Pacira Biosciences, Stock Analysis
PCRX Stock | USD 17.55 0.17 0.98% |
Pacira BioSciences, is undervalued with Real Value of 26.64 and Target Price of 55.1. The main objective of Pacira BioSciences, stock analysis is to determine its intrinsic value, which is an estimate of what Pacira BioSciences, is worth, separate from its market price. There are two main types of Pacira BioSciences,'s stock analysis: fundamental analysis and technical analysis.
The Pacira BioSciences, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pacira BioSciences, is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Pacira Stock trading window is adjusted to America/New York timezone.
Pacira |
Pacira Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.08. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacira BioSciences, recorded a loss per share of 1.98. The entity had not issued any dividends in recent years. Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 697 people. To find out more about Pacira BioSciences, contact David Stack at 813 553 6680 or learn more at https://www.pacira.com.Pacira BioSciences, Quarterly Total Revenue |
|
Pacira BioSciences, Investment Alerts
Over 98.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: Pacer Advisors Inc. Acquires 2,799,434 Shares of Pacira BioSciences, Inc. - MarketBeat |
Pacira BioSciences, Upcoming and Recent Events
Earnings reports are used by Pacira BioSciences, to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
27th of February 2024 Upcoming Quarterly Report | View | |
1st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Pacira Largest EPS Surprises
Earnings surprises can significantly impact Pacira BioSciences,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2015-07-30 | 2015-06-30 | 0.23 | 0.2 | -0.03 | 13 | ||
2015-04-30 | 2015-03-31 | 0.2 | 0.23 | 0.03 | 15 | ||
2019-05-02 | 2019-03-31 | 0.26 | 0.22 | -0.04 | 15 |
Pacira BioSciences, Environmental, Social, and Governance (ESG) Scores
Pacira BioSciences,'s ESG score is a quantitative measure that evaluates Pacira BioSciences,'s performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Pacira BioSciences,'s operations that may have significant financial implications and affect Pacira BioSciences,'s stock price as well as guide investors towards more socially responsible investments.
Pacira Stock Institutional Investors
Shares | Marshall Wace Asset Management Ltd | 2024-06-30 | 971.1 K | Rock Springs Capital Management Lp | 2024-06-30 | 785 K | Nuveen Asset Management, Llc | 2024-06-30 | 711.2 K | Hhg Plc | 2024-06-30 | 698.4 K | Schroder Investment Management Group | 2024-06-30 | 616.8 K | Jpmorgan Chase & Co | 2024-06-30 | 600.6 K | Bank Of America Corp | 2024-06-30 | 559 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 554.4 K | Assenagon Asset Management Sa | 2024-09-30 | 553.1 K | Blackrock Inc | 2024-06-30 | 8 M | Vanguard Group Inc | 2024-09-30 | 5.3 M |
Pacira Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 810.34 M.Pacira Profitablity
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.05 | 0.05 | |
Return On Capital Employed | 0.06 | 0.06 | |
Return On Assets | 0.03 | 0.03 | |
Return On Equity | 0.05 | 0.05 |
Management Efficiency
Pacira BioSciences, has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1148) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 18.83 | 19.77 | |
Tangible Book Value Per Share | 4.84 | 5.08 | |
Enterprise Value Over EBITDA | 12.23 | 11.62 | |
Price Book Value Ratio | 1.79 | 1.70 | |
Enterprise Value Multiple | 12.23 | 11.62 | |
Price Fair Value | 1.79 | 1.70 | |
Enterprise Value | 1.7 B | 1.8 B |
The strategic initiatives led by Pacira BioSciences,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin 0.1302 | Profit Margin (0.13) | Beta 0.818 | Return On Assets 0.0417 | Return On Equity (0.11) |
Technical Drivers
As of the 25th of November, Pacira BioSciences, holds the Coefficient Of Variation of 631.55, risk adjusted performance of 0.1282, and Semi Deviation of 1.95. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacira BioSciences,, as well as the relationship between them.Pacira BioSciences, Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pacira BioSciences, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pacira BioSciences,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Pacira BioSciences, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira BioSciences, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira BioSciences,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacira BioSciences, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pacira BioSciences, Outstanding Bonds
Pacira BioSciences, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pacira BioSciences, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pacira bonds can be classified according to their maturity, which is the date when Pacira BioSciences, has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
PKG 305 01 OCT 51 Corp BondUS695156AW92 | View | |
US695156AV10 Corp BondUS695156AV10 | View | |
US695156AU37 Corp BondUS695156AU37 | View | |
PACKAGING P AMER Corp BondUS695156AT63 | View | |
PACIFICORP 625 percent Corp BondUS695114CG18 | View | |
PACIFICORP 61 percent Corp BondUS695114CB21 | View |
Pacira BioSciences, Predictive Daily Indicators
Pacira BioSciences, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pacira BioSciences, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pacira BioSciences, Corporate Filings
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 23rd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 21st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 27th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 9th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Pacira BioSciences, Forecast Models
Pacira BioSciences,'s time-series forecasting models are one of many Pacira BioSciences,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pacira BioSciences,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Pacira Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Pacira BioSciences, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pacira shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pacira BioSciences,. By using and applying Pacira Stock analysis, traders can create a robust methodology for identifying Pacira entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.09 | 0.10 | |
Operating Profit Margin | 0.13 | 0.14 | |
Net Profit Margin | 0.06 | 0.07 | |
Gross Profit Margin | 0.73 | 0.38 |
Current Pacira Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pacira analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pacira analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
55.1 | Buy | 9 | Odds |
Most Pacira analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pacira stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pacira BioSciences,, talking to its executives and customers, or listening to Pacira conference calls.
Pacira Stock Analysis Indicators
Pacira BioSciences, stock analysis indicators help investors evaluate how Pacira BioSciences, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pacira BioSciences, shares will generate the highest return on investment. By understating and applying Pacira BioSciences, stock analysis, traders can identify Pacira BioSciences, position entry and exit signals to maximize returns.
Begin Period Cash Flow | 104.1 M | |
Long Term Debt | 513.8 M | |
Common Stock Shares Outstanding | 52 M | |
Total Stockholder Equity | 870.1 M | |
Tax Provision | 2.9 M | |
Quarterly Earnings Growth Y O Y | -0.245 | |
Property Plant And Equipment Net | 234.9 M | |
Cash And Short Term Investments | 278.6 M | |
Cash | 153.3 M | |
Accounts Payable | 15.7 M | |
Net Debt | 432.7 M | |
50 Day M A | 16.2058 | |
Total Current Liabilities | 97.4 M | |
Other Operating Expenses | 587.3 M | |
Non Current Assets Total | 1.1 B | |
Forward Price Earnings | 5.1177 | |
Non Currrent Assets Other | 36 M | |
Stock Based Compensation | 47.9 M |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.